-
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
•
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Centurium Capital and 6 Dimensions Capital, with contributions from Shanghai Jiading Industrial Development Group, Shanghai Jiajia Group, Hefei Haiheng Holdings, Hefei Industrial…
-
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first patient dosing in a Phase Ib/II clinical study for its antibody-drug conjugate (ADC) 9MW2821, which targets Nectin-4. The study is designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of 9MW2821 in combination with…
-
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
•
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study with the enrollment and dosing of the first patient for its delgocitinib cream, marking the first clinical study for the product in China. This milestone signifies the company’s efforts to address moderate to severe adult…
-
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
•
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at enhancing access to drugs from the National Reimbursement Drug List (NRDL). This program involves 23 designated medical institutions within the city, chosen for their high outpatient volumes and low procurement of national negotiation drugs, which…
-
Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics
•
The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based procurement (VBP) for the Beijing-Tianjin-Hebei region, covering a total of 37 drugs, including biological agents such as coagulation factors, fibrinogen, and human serum albumin. This initiative aims to streamline drug procurement processes and ensure cost-effective…
-
Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments
•
Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene therapies for hearing loss, following an agreement reached last month. This strategic move expands Regeneron’s portfolio in the field of genetic therapies and underscores the company’s commitment to addressing hearing loss conditions. Decibel’s Pipeline and…
-
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company Valo Health. The collaboration aims to leverage Valo Health’s patient genetic database, artificial intelligence (AI) capabilities, and tissue modelling platform for the target identification, discovery, and development of novel treatments for cardiometabolic diseases. Additionally, Novo…
-
Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast
•
Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the progress of its programmed death-1 (PD-1) inhibitor, toripalimab, at the US Food and Drug Administration (FDA). Toripalimab is under license from China’s Junshi Biosciences (HKG: 1877; SHA: 688180). The FDA has completed its clinical study…
